A study on the correlation between serum levels of fibroblast growth factor-19 and cardiovascular risk factors in patients with metabolic syndrome

S Aruna; P Suriyaprabha; Krishnaprabha Krishnaprabha; J Sowndharya; K Suganya; K. Shanmugasundaram

doi:10.53730/ijhs.v6nS1.8722

Authors

Aruna. S Assistant Professor, Department of Biochemistry, Government Karur Medical College & Hospital, Karur, Tamilnadu, India
Suriyaprabha. P Assistant Professor, Department of Pathology, Government Karur Medical College & Hospital, Karur, Tamilnadu, India
Krishnaprabha Tutor, Department of Biochemistry, Government Karur Medical College & Hospital, Karur, Tamilnadu, India
Sowndharya. J Senior Assistant Professor, Department of Biochemistry, Government Karur Medical College & Hospital, Karur, Tamilnadu, India
Suganya. K Assistant professor, Department of Physiology, SRMC & RI, SRIHER, Porur, Chennai, Tamilnadu, India
K. Shanmugasundaram
dr.kssundar@gmail.com
Assistant Professor, Department of General Medicine, Government Karur Medical College & Hospital, Karur, Tamilnadu, India

Keywords:

Metabolic syndrome, Fibroblast Growth factor 19 (FGF 19), Total Cholesterol (TC), HDL-cholesterol, Anthrogenic index of plasma (AIP)

Abstract

Metabolic syndrome is a major global threat nowadays due to urbanization, sedentary life style and increased incidence of obesity. FGF-19 has recently been introduced as a novel marker regulating metabolism, reversing diabetes mellitus, hyper lipidemia, hepatic steatosis and adiposity. Aim & Objective: To compare the serum Fibroblast Growth Factor 19 levels of metabolic syndrome patients with healthy individuals. To analyze the correlation between serum FGF 19 and the components of metabolic syndrome. Materials & Methods: A total of 50 patients and 50 controls were included in the study. After obtaining informed consent, anthropometric measures (Height, Weight, BMI & Waist circumference) were taken. Blood investigations such as FGF 19, TC, HDL-cholesterol were estimated and LDL, VLDL & AIP levels were calculated. Statistical Analysis: Student’s t-test was employed for the statistical analysis and data were expressed in terms of mean and standard deviation. ‘p’ value less than 0.05 is considered as statistically significant. Correlation between the measured parameters was assessed using Pearson’s correlation coefficient. Result & Conclusion: Serum levels of FGF 19 were low in patients with metabolic syndrome.

Downloads

Download data is not yet available.

References

Jaspinder Kaur; A Comprehensive Review on Metabolic Syndrome; Cardiology Research and Practice Volume 2014, Article ID 943162, 21 pages.

Sushant Bhatnagar, Holly A. Damron, and F. Bradley Hillgartner; Fibroblast Growth Factor-19, a Novel Factor That Inhibits Hepatic Fatty Acid Synthesis; The Journal Of Biological Chemistry Vol. 284, No. 15, pp. 10023–10033, April 10, 2009.

Thierry Claudel, Bart Staels, Folkert Kuipers; The Farnesoid X Receptor A Molecular Link between Bile Acid and Lipid and Glucose Metabolism; Arterioscler Thromb Vasc Biol. 2005; 25:2020-2030.

Xinqiang Huang, Chaofeng Yang, Yongde Luo, Chengliu Jin, Fen Wang, and Wallace L. McKeehan; FGFR4 Prevents Hyperlipidemia and Insulin Resistance but Underlies High-Fat Diet–Induced Fatty Liver; DIABETES, VOL. 56, OCTOBER 2007 pg.2501-2510.

Xinle Wu, Hongfei Ge, Jamila Gupte, Jennifer Weiszmann, Grant Shimamoto, Jennitte Stevens, Nessa Hawkins, Bryan Lemon, Wenyan Shen, Jing Xu, Murielle M. Veniant, Yue-Sheng Li, Richard Lindberg, Jin-Long Chen, Hui Tian, and Yang Li; Co-receptor Requirements for Fibroblast Growth Factor-19 Signaling; The journal of biological chemistry vol. 282, no. 40, pp. 29069–29072, october 5, 2007.

Karen K. Ryan, Rohit Kohli, Ruth Gutierrez-Aguilar, Shrawan G. Gaitonde, Stephen C. Woods, and Randy J. Seeley; Fibroblast Growth Factor-19 Action in the Brain Reduces Food Intake and Body Weight and Improves Glucose Tolerance in Male Rats; Endocrinology, January 2013, 154(1):9–15.

Qichen Fang, MS., Huating Li, MD, PHD., Qianqian Song, MD., Wenjing Yang, MD., Xuhong Hou, MS., Xiaojing Ma, MD., Junxi Lu, BS., Aimin Xu, PHD., Weiping Jia, MD, PHD.; Serum Fibroblast Growth Factor 19 Levels Are Decreased in Chinese Subjects With Impaired Fasting Glucose and Inversely Associated With Fasting Plasma Glucose Levels; Diabetes Care 36:2810–2814, 2013.

Serkan Kir, Sara A. Beddow, Varman T. Samuel, Paul Miller, Stephen F. Previs, Kelly Suino-Powell, H. Eric Xu, Gerald I. Shulman, Steven A. Kliewer, and David J. Mangelsdorf; FGF19 as a Postprandial, Insulin-Independent Activator of Hepatic Protein and Glycogen Synthesis; Science. 2011 March 25; 331(6024): 1621–1624. doi:10.1126/science.1198363.

Burcu Barutcuoglu, Gunes Basol, Yasemin Cakir, Sevki Cetinkalp, Zuhal Parildar, Ceyda Kabaroglu, Dilek Ozmen, Isil Mutaf, Oya Bayindir; Fibroblast Growth Factor-19 Levels in Type 2 Diabetic Patients with Metabolic Syndrome; Annals of Clinical & Laboratory Science, vol. 41, no. 4, 2011 pg.390-396.

Kwang-Hoon Song, Tiangang Li, Erika Owsley, Stephen Strom, and John Y. L.Chiang; Bile acids activate fibroblast growth factor 19 signaling in human hepatocytes to inhibit cholesterol 7α-hydroxylase gene expression; Hepatology. 2009 January; 49(1): 297–305. doi:10.1002/hep.22627.

John B. Buse, Kenneth S. Polonsky, Charles F. Burant, Chapter 31, Type 2 Diabetes Mellitus, Shlomo Melmed, Kenneth S. Polonsky, P. Reed Larsen, Henry M. Kronenberg, Williams Textbook Of Endocrinology, 12th Edition, Published By SAUNDERS, Elsevier, 2011, Pages 1389-1392.

Chapter 27, Energy Metabolism: Integration and Organ Specialization, Donald Voet, Judith G.Voet, Biochemistry, Fourth Edition, Published By WILEY, 2011, Page 1104.

David B. Sacks, M.B., Ch.B.,F.R.C. Path., chapter-46, Diabetes Mellitus, Carl A.Burtis, Edward R.Ashwood, David E.Bruns, Tietz Textbook Of Clinical Chemistry And Molecular Diagnostics, Fifth Edition, published by SAUNDERS, Elsevier, 2012, page 1430.

JM Gallego-Escuredo, J Gómez-Ambrosi, V Catalan, P Domingo, M Giralt, G Frühbeck and F Villarroya; Opposite alterations in FGF21 and FGF19 levels and disturbed expression of the receptor machinery for endocrine FGFs in obese patients; International Journal of Obesity (2015) 39, 121–129.

Xinle Wu , Hongfei Ge , Hélène Baribault , Jamila Gupte , Jennifer Weiszmann , Bryan Lemon , Jonitha Gardner , Preston Fordstrom , Jie Tang , Mingyue Zhou , Minghan Wang , and Yang Li; Dual actions of fibroblast growth factor 19 on lipid metabolism; Journal of Lipid Research Volume 54, 2013 pg..325-332.

Andrew Beenken and Moosa Mohammadi; The FGF family: biology, pathophysiology and therapy; Nature Reviews | Drug Discovery Volume 8 | March 2009 | 235-253.

Tim C. M. A. Schreuder, Hendrik A. Marsman, Martin Lenicek, Jochem R. van Werven, Aart J. Nederveen, Peter L. M. Jansen, and Frank G. Schaap; The hepatic response to FGF19 is impaired in patients with nonalcoholic fatty liver disease and insulin resistance; Am J Physiol Gastrointest Liver Physiol 298: G440–G445, 2010.

Ken-ichi Tomiyama, Ryota Maeda, Itaru Urakawa, Yuji Yamazaki, Tomohiro Tanaka, Shinji Ito, Yoko Nabeshima, Tsutomu Tomita, Shinji Odori, Kiminori Hosoda, Kazuwa Nakao, Akihiro Imura, and Yo-ichi Nabeshima; Relevant use of Klotho in FGF19 subfamily signaling system in vivo; 1666–1671 | PNAS | January 26, 2010 | vol. 107 | no. 4.

Dongyu Wang, Wenjing Zhu, Jieming Li, Chongyou An, Zilian Wang; Serum Concentrations of Fibroblast Growth Factors 19 and 21 in Women with Gestational Diabetes Mellitus: Association with Insulin Resistance, Adiponectin, and Polycystic Ovary Syndrome History; PLOS ONE November 2013 | Volume 8 | Issue 11 | e81190 pg... 1- 8.

Bo Isomaa, MD, Peter Almgren, MSC, Tiinamaija Tuomi, MD, Bjo Rn Forse N, MD, Kaj Lahti, MD, Michael Nisse´N, MD, Marja-Riitta Taskinen, MD, Leif Groop, MD; Cardiovascular Morbidity and Mortality Associated With the Metabolic Syndrome; DIABETES CARE, VOLUME 24, NUMBER 4, APRIL 2001 pg. 683-689.

Scott M. Grundy, MD, PHD; Metabolic Syndrome: Connecting and Reconciling Cardiovascular and Diabetes Worlds; JACC Vol. 47, No. 6, 2006, Metabolic Syndrome CVD and Diabetes March 21, 2006:1093–1100.

Harold E.Lebovitz, Chapter 13.3.6, Metabolic Syndrome, John A.H.Wass, Paul M.Stewart, Diabetes Section Edited By Stephanie A.Amiel, Melanie J.Davies, Oxford Textbook Of Endocrinology And Diabetes, Published By Oxford University Press, 2011, Pages 1764-1771.

Widana, I.K., Sumetri, N.W., Sutapa, I.K., Suryasa, W. (2021). Anthropometric measures for better cardiovascular and musculoskeletal health. Computer Applications in Engineering Education, 29(3), 550–561. https://doi.org/10.1002/cae.22202

Jianjun Wang, Sanna Ruotsalainen, Leena Moilanen, Paivi Lepisto, Markku Laakso, and Johanna Kuusisto; The metabolic syndrome predicts cardiovascular mortality: a 13-year follow-up study in elderly non-diabetic Finns; European Heart Journal (2007) 28, 857–864.

Zhang Jing, Li Hua Ting, Fang Qi Chen, And Jia Wei Ping; Role Of Fibroblast Growth Factor 19 In Maintaining Nutrient Homeostasis And Disease; Biomed Environ Sci, 2014; 27(5): 319-324.